Attitudes, Beliefs, and Intention to Receive a COVID-19 Vaccine for Pediatric Patients With Sickle Cell Disease

Lisa M. Shook,Brittany L. Rosen,Constance A. Mara,Cami Mosley,Alexis A. Thompson,Kim Smith-Whitley,Lisa Schwartz,Christina Barriteau,Allison King,Eniola Oke,Fatoumatou Jallow,Bridget Murphy,Lori Crosby
DOI: https://doi.org/10.1097/mph.0000000000002877
2024-06-25
Journal of Pediatric Hematology/Oncology
Abstract:Adults and children with sickle cell disease (SCD) are at increased risk of developing SCD-related complications in response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection 1 including acute chest syndrome, severe pain crises (vaso-occlusive episode), strokes, and changes in kidney function. 1 Immunizations have been developed for SARS-CoV-2 and found to significantly reduce disease severity and mortality 2,3 and COVID-19 vaccines have now been approved and recommended for those aged 6 months and older . Despite this, a significant portion of children and adolescents remain unvaccinated, with even lower rates for booster shots. As of April 2023, it is estimated that ∼40% of adolescents (12 to 17 y old) and 34% of young adults (18 to 24 y old) have not completed the COVID-19 vaccine 2-dose series (CDC). 4 The rates for COVID-19 booster for this population are significantly lower: 7.7% of 12- to 17-year olds and 7.3% of 18- to 24-year olds who are fully vaccinated have received a booster. 4 This trend is concerning, particularly in light of potential annual booster recommendations by the FDA and CDC. 5
oncology,pediatrics,hematology
What problem does this paper attempt to address?